Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia

Pediatric Blood and Cancer

Volumn 47, Issue 6, 2006, Pages 765-772

  Brunet, A S ^a   Ploton, C ^a   Galambrun, C ^a   Pondarre C ^a   Pages, M P ^a   Bleyzac, N ^a   Freydiere A M ^a   Barbe G ^a   Bertrand, Y ^a  

^a HÔPITAL DEBROUSSE   (France)

Author keywords

Acute myeloid leukemia; Children; Infectious prophylaxis; Streptococcus; Vancomycine mouthwash; Viridans

Indexed keywords

AMIKACIN; AMPHOTERICIN B; CHLORHEXIDINE; COTRIMOXAZOLE; CYTARABINE; IDARUBICIN; PIPERACILLIN; RETINOIC ACID; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; CHILD; CLINICAL TRIAL; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTIOUS COMPLICATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; STAPHYLOCOCCUS; STOMACH LAVAGE; STREPTOCOCCUS;

ACUTE DISEASE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INFECTION CONTROL; LEUKEMIA, MYELOID; MALE; RETROSPECTIVE STUDIES; SEPSIS; STREPTOCOCCAL INFECTIONS; SURVIVAL RATE; TREATMENT OUTCOME; VIRIDANS STREPTOCOCCI;

EID: 33749182047     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20706     Document Type: Article

References (37)

1. Behar C, Suciu S, Benoit Y, et al. Mitoxantrone containing regimen for treatment of childhood acute leukemia and analysis of prognostic factors: Results of the EORTC Children Leukemia Cooperative Study 58872. Medical Pediatr Oncol 1996;26:173-179.
2. Creutzig U, Ritter H, Langermann HJ, et al. Improved treatment results in childhood acute myelogenous leukemia: A report of the German cooperative study AML-BFM-78. Blood 1985;65:298-304.
3. Woods WG, Kobrinsky N, Buckley J, et al. Intensively timed induction therapy followed by autologous or allogenic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: A Children's Cancer Group pilot study. J Clin Oncol 1993;11:1448-1457.
4. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from Children's Cancer Group. Blood 1996;87:4979-4989.
5. Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AML-BFM-83 as compared with study AML-BFM-78. Blood 1990;75:1932-1940.
6. Mehta J, Powles R, Singhal S, et al. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia. Semin Hematol 1996;33:18-23.
7. Wolf SN, Herzig RH, Fay JW, et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: Long-term follow-up and results. J Clin Oncol 1989;7:1260-1267.
8. Ravindranath Y, Steuber CP, Krischer J, et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: A Pediatric Oncology Group Study. J Clin Oncol 1991;9:572-580.
9. Creutzig U, Ritter J, Zimmermann M, et al. Improved treatments results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: Results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol 2001;19:2705-2713.
10. Chang M, Raimondi SC, Ravindranath Y, et al. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): Univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study. Leukemia 2000;14:1201-1207.
11. Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia: Analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 2004;18:72-77.
12. Okamoto Y, Ribeiro RC, Kumar Srivastava D, et al. Viridans streptococcal sepsis: Clinical features and complications in childhood acute myeloid leukemia. J Pediatr Hematol Oncol 2003;25:696-703.
13. Gassas A, Grant R, Richardson S, et al. Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplants recipients. J Clin Oncol 2004;22:1222-1227.
14. Gamis AS, Howells WB, DeSwarte-Wallace J, et al. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: A report from the Children's Cancer Group study CCG-2891. J Clin Oncol 2000;18:1845-1855.
15. Persson L, Vikerfors T, Sjoberg L, et al. Increased incidence of bacteraemia due to viridans streptococci in an unselected population of patients with acute myeloid leukaemia. Scand J Infect Dis 2000;32:615-621.
16. Entz-Werle N, Suciu S, Otten J, et al. Overall results and relative value of chemotherapy vs. allogeneic bone marrow transplantation (BMT) in first complete remission in acute myeloblastic leukemia (AML) patients: First results of the EORTC Children Leukemia Group trial 58921. Leukemia 2005 (accepted).
17. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002;34:7-14.
18. Riley LC, Hann IM, Wheatley K, et al. Treatment-related deaths during induction and first remission of AML in children treated on the Tenth Medical Research Council acute myeloid leukemia trial (MRC AML 10). The MCR childhood leukemia working party. Br J Haematol 1999;106:436-444.
19. Feusner JH, Hastings CA. Infections in children with acute myelogenous leukemia. Concepts of management and prevention. J Pediatr Hematol Oncol 1995;17:234-247.
20. Pizzo PA, Robichaud KJ, Wesley R, et al. Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine (Baltimore) 1982;61:153-165.
21. Girmenia C, Lo Coco F, Breccia M, et al. Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen. Leukemia 2003;17:925-930.
22. Ammann RA, Hirt A, Ridolfi Luthy A, et al. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol 2003;41:436-443.
23. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: Emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999;29:490-494.
24. Velasco E, Byington R, Martins CAS, et al. Prospective evaluation of the epidemiology, microbiology and outcome of bloodstream infections in hematologic patients in a single cancer center. Eur J Clin Microbiol Infect Dis 2003;22:137-143.
25. Bochut PY, Eggiman P, Calandra T, et al. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: Clinical spectrum and risk factors. Clin Infect Dis 1994;18:25-31.
26. Bilgrami S, Feingold JM, Dorsky D, et al. Streptococcus viridans bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1998;21:591-595.
27. Martino R, Manteiga R, Sanchez I, et al. Viridans streptococcal shock syndrome during bone marrow transplantation. Acta Haematol 1995;94:69-73.
28. Cordonnier C, Buzyn A, Leverger G, et al. Epidemiology and risk factors for Gram-positive coccal infections in neutropenia: Toward a more targeted antibiotic strategy. Clin Infect Dis 2003;36:149-158.
29. Barbé G, Souillet G, Ploton C, et al. Reliability of controlled decontamination for preventing bacteremias in bone marrow transplantation: A ten-year experience in a paediatric unit. Abstr. 43 9p. In abstract of the 7th European Congress of Clinical Microbiology and Infectious Diseases. 1995, Vienna, Austria.
30. Barker GJ, Call SK, Gamis AS. Oral care with vancomycin paste for reduction in incidence of alpha-hemolytic streptococcal sepsis. J Pediatr Hematol Oncol 1995;2:151-155.
31. Barbé G, Ploton C, Pondarré C, et al. Vancomycin-resistant enterococci in pediatric hematology: No panic please!(in French). Path Biol 1998;46:408-411.
32. Padiglione AA, Wolfe R, Grabsch EA, et al. Risk factors for new detection of vancomycin-resistant enterococci in acute-care hospitals that employ strict infection control procedures. Antimicrob Agents Chemother 2003;47:2492-2498.
33. Montecalvo MA, Horowitz HV, Nadelman R, et al. Controlling IV Vancomycin on an oncology unit by infectious diseases consultation. Abstr N 15 p 138. ICAAC San Francisco 17-20/09/1995.
34. Eltings LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: A case-control study of predisposing factors. Clin Infect Dis 1992;14:1201-1207.
35. Feusner JH, Alonzo TA, Dinndorf P, et al. Infectious complications of intensive chemotherapy on children's cancer group protocol CCG-2961 for pediatric acute myeloid leukemia. Blood 2002;100:332a; abstract 1287.
36. Grigull L, Beier R, Schrauder A, et al. Invasive fungal infections are responsible for one-fifth of the infectious death in children with ALL. Mycoses 2003;46:441-446.
37. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751.